FreeCME

Beyond ACEis and ARBs: The Promise of SGLT2 Inhibition to Reduce Risk of ESRD and Dialysis in Numerous Patient Populations

CME: 1.0

Target Audience

The educational design of this activity addresses the needs of nephrologists, cardiologists, endocrinologists, internal medicine physicians, primary care physicians, nurse practitioners and physician assistants. Secondary audiences include clinical pharmacists, nurses, and other clinicians who care for patients who are at risk for CKD or at high risk of progression.

Statement of Need/Overview

Recently, SGLT2 inhibitors have been shown to slow the progression of chronic kidney disease (CKD), independent of whether the patient has diabetes. However, CKD is a silently progressive disease and most patients do not have their kidney function evaluated regularly, leaving many patients with CKD that is not recognized until it is in an advanced stage.

Join a panel of expert clinicians to explore strategies to recognize predisposing risk factors for CKD and improve the timeliness of referrals to specialists. Panelists will review the most recent data on SGLT2 inhibitors in advanced kidney disease and demonstrate how to apply that evidence in a variety of patient scenarios. Clinicians will learn about dosage and titration, use of SGLT2 inhibitors with RAS inhibition, and impacts on blood pressure, intraglomerular pressure, and hyperfiltration.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Develop strategies for multidisciplinary care team members to assess kidney function in high-risk people because of race/ethnicity and/or the presence of predisposing conditions
  • Summarize the evidence supporting the impact of SGLT2 inhibitors on the progression of CKD, including conversion to end-stage renal disease (ESRD), in patients with advanced CKD independent of impacts on co-existing conditions
  • Describe the mechanisms by which SGLT2 inhibitors slow down progression of CKD to ESRD, including impacts on blood pressure, intraglomerular pressure, and hyperfiltration

Post a comment to this article